Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Adult T-cell leukaemia/lymphoma, drawn from the whole corpus: 7 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
The treatment of this disease rests on consensus rather than on randomised evidence, and the authors of the consensus say so.
The virus is preventable. Antenatal screening and avoidance of breastfeeding where it is safe to do so reduce transmission, and most of the world does not screen.
The incidence is rising in the places that do not expect it, including the United States and non-endemic Japan, while remaining stable where it is endemic.
Drugs approved for this disease in Japan, including mogamulizumab and later agents, are not approved in much of the world, so the people least likely to be offered them are those who moved away from where the disease is studied.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 14 changes by month →When this page itself was last checked or edited.
Overall response 48.
HTLV-1 serology belongs in the work-up of any T-cell lymphoma or leukaemia in a person who comes from, or whose parents come from, south-western Japan, the Caribbean, west or central Africa, parts of South America, Iran or Romania. Without the test the disease is reported as peripheral T-cell lymphoma not otherwise specified and treated on a pathway that does not fit it. A positive test is followed by confirmation that the virus is clonally integrated in the tumour cells, because asymptomatic infection is common in those populations and does not by itself mean lymphoma.
Confirmed overall response 11 per cent with mogamulizumab against 0 per cent with chemotherapy; progression-free survival hazard ratio 0.
The revised report added the classification of cutaneous disease, disease in the central nervous system, the management of older and transplant-ineligible patients, upfront allogeneic transplant and newer agents, and stated that a best practice approach was adopted because the clinical evidence was of lower quality.
Complete response 52 against 33 per cent with the addition of mogamulizumab, with more toxicity; no survival endpoint was primary.